26 March 2024 - Norgine today announced that the CHMP of the EMA has adopted a positive opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia.

NPJ5008 is a novel formulation of dantrolene that has been developed by Norgine to shorten preparation and administration times versus Dantrium IV (dantrolene sodium).

Read Norgine press release